Summary

Your ADRB1 result determines how your heart's beta-1 receptors respond to adrenaline and beta-blocker medications — the Arg389 variant produces a more reactive cardiovascular system with stronger heart rate and blood pressure responses to stress and exercise, while the Gly389 variant is less reactive and responds less to standard beta-blocker doses.

Genotype spectrum

CC (Arg/Arg — High receptor activity)

Your cardiovascular system is highly responsive. You get a stronger cardiac output boost during exercise, which can support high-intensity performance.

CG/GC (Arg/Gly — Intermediate)

Balanced cardiovascular reactivity. You get adequate cardiac response to exercise and stress without the extremes of either homozygous state.

GG (Gly/Gly — Reduced receptor activity)

Your cardiovascular system is more resilient to catecholamine surges. Where Arg/Arg carriers get palpitations from caffeine, you're more likely to tolerate stimulants without cardiac symptoms.

Practical takeaway

For CC Carriers (Arg/Arg — Enhanced Receptor Activity)

Exercise monitoring:
• Your heart rate during exercise may run 5-10 bpm higher than age-predicted norms at equivalent intensities. Use RPE alongside HR to calibrate zones.
• Warm-up may feel like HR rises quickly — this is normal for your genotype. You reach target HR faster.
• HIIT training is effective for you — your cardiovascular system responds robustly to high-intensity intervals.
• Post-exercise recovery HR may also be faster (stronger parasympathetic rebound).

Stimulant management:
• Caffeine, pre-workout supplements, and other sympathomimetics produce stronger cardiovascular effects in you. If you experience palpitations, racing heart, or anxiety with caffeine, consider reducing dose or switching to L-theanine + caffeine combinations.
• Your CYP1A2 genotype compounds this — if you're also a slow caffeine metaboliser, the combination of prolonged caffeine exposure + enhanced cardiac receptor sensitivity is significant.

Stress response:
• Your cardiovascular stress reactivity is higher. This doesn't mean you're more stressed — but your heart responds more to the same level of stress.
• Vagal tone practices (slow breathing, HRV training) may be particularly beneficial for counteracting enhanced sympathetic cardiac reactivity.

If prescribed beta-blockers:
• You're likely to respond well at standard or lower-than-standard doses. Report this genotype to your prescriber.
For GG Carriers (Gly/Gly — Reduced Receptor Activity)

Exercise calibration:
• Your heart rate response to exercise is blunted. HR may plateau lower than expected for a given workload.
• Use RPE as your primary intensity guide, not HR zones alone. A given HR may represent a higher relative effort for you compared to population-average HR zone charts.
• You may need longer warm-ups to reach target HR zones.
• Consider lactate-based or ventilatory threshold testing for precise zone calibration if you train seriously.

Stimulant tolerance:
• You're more tolerant of caffeine's cardiac effects (though central nervous system effects are separate — anxiety may still occur via ADORA2A pathways).

If prescribed beta-blockers:
• Flag your genoty

Evidence detail

What This Gene Does

ADRB1 encodes the beta-1 adrenergic receptor, the primary receptor on heart muscle cells that detects adrenaline (epinephrine) and noradrenaline (norepinephrine). When your sympathetic nervous system fires — during exercise, stress, fear, excitement — catecholamines bind to beta-1 receptors on cardiac cells and increase heart rate (chronotropy), strengthen contractions (inotropy), and accelerate conduction (dromotropy). This is the receptor that makes your heart beat faster and harder when you need it to.

The rs1801253 variant (Arg389Gly) sits in the intracellular signalling domain of the receptor. The Arg389 version couples more efficiently to the stimulatory G-protein (Gs), producing a stronger intracellular cAMP response per unit of catecholamine. The Gly389 version couples less efficiently — the receptor still works but generates a weaker signal per catecholamine molecule.

Mechanism

The receptor-G-protein coupling story:

The beta-1 adrenergic receptor is a seven-transmembrane GPCR. When catecholamines bind the extracellular domain, the receptor undergoes a conformational change that activates the associated Gs (stimulatory G-protein) on the intracellular side. Gs activates adenylyl cyclase → cAMP production → PKA activation → increased calcium channel opening → stronger, faster heartbeats.

The Arg389Gly polymorphism sits at position 389 in the receptor's fourth intracellular loop — the domain that directly contacts Gs. Arginine at position 389 creates a more favourable electrostatic interaction with Gs, enhancing coupling efficiency by ~3-fold (Mason et al. 1999). This means the same amount of adrenaline produces a stronger cardiac response in Arg389 carriers.

Why this affects exercise:

During exercise, sympathetic activation releases catecholamines that drive heart rate and contractility upward. Arg389 carriers get more cardiac output per unit of catecholamine — their heart rate rises faster and higher, and their stroke volume increases more. This means their HR training zones may shift upward compared to Gly389 carriers at the same relative exercise intensity.

Why this affects beta-blockers:

Beta-blockers work by competitively blocking catecholamine binding at beta-1 receptors. In Arg389 carriers, there's more signal to block (higher baseline receptor activity), so beta-blockers have a larger absolute effect. In Gly389 carriers, the baseline signal is lower, so there's less to block — hence the reduced efficacy at standard doses. This isn't a failure of the drug; it's a difference in the target.

Why this affects stress response:

Psychological stress activates the sympathetic nervous system and raises circulating catecholamines. Arg389 carriers translate this into a larger cardiovascular response — higher heart rate spike, higher blood pressure, more forceful contractions. This is why some people feel their heart "pounding" during stress while others don't — it's partly receptor genetics.

ADRB1 Beta Receptor

Summary

Genotype spectrum

Practical takeaway

Evidence detail

Sources (7)